THERAPY DOSSIER · th-0a2b71b25e3d

Recombinant nAG protein

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28689525 ↗2017Reported benefit

The Use of Recombinant nAG Protein in Spinal Cord Crush Injury in a Rat Model.

RatCrushSpinal crushSprague-Dawley (per MeSH indexing)Male (per MeSH indexing)n = 8 rats in total: 4 control and 4 experimentalSingle intra-dural injectionImmediately after the injury

Model: Acute spinal cord crush injury using the aneurysm clip injury model

Weight was maintained in nAG-treated rats but not controls, and from 3 weeks after injury motor recovery was significantly better in the treated group (p less than 0.05). MRI at 6 weeks showed better cord continuity and less fluid accumulation, and histology showed less gliosis, tissue architecture…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…